Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 5/20 | 0.47 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3229461 | 1.00 | SCD (0.47) | SCDGLSAOC3PTPN11DCTPP1 | |
| SCHEMBL3224982 | 0.91 | SCD (0.46) | SCDAOC3DCTPP1 | |
| SCHEMBL3224990 | 0.91 | SCD (0.46) | SCDAOC3DCTPP1 | |
| SCHEMBL3231690 | 0.87 | DCTPP1 (0.52) | SCDDCTPP1 | |
| SCHEMBL3231697 | 0.87 | DCTPP1 (0.52) | SCDDCTPP1 | |
| SCHEMBL3220070 | 0.85 | SCD (0.51) | SCDDCTPP1 | |
| SCHEMBL3220064 | 0.85 | SCD (0.51) | SCDDCTPP1 | |
| SCHEMBL3215899 | 0.85 | SCD (0.47) | SCDDCTPP1KDM4EHSD17B10 | |
| SCHEMBL3215906 | 0.85 | SCD (0.47) | SCDDCTPP1KDM4EHSD17B10 | |
| SCHEMBL3230328 | 0.84 | HSD11B1 (0.43) | SCDAOC3PTPN11KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575167-B2 | Spiro compounds having stearoyl-CoA desaturase action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | SCD, SPR, SCD5 | SCD 1/4885GLS 540/4885AOC3 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.